首页 > 最新文献

Russian Journal of Cardiology最新文献

英文 中文
Growth differentiation factor-15 — a new indicator of unfavorable prognosis in uncomplicated myocardial infarction 生长分化因子-15——无并发症心肌梗死不良预后的新指标
Q3 Medicine Pub Date : 2023-09-21 DOI: 10.15829/1560-4071-2023-5381
A. S. Sabirzyanova, A. S. Galyavich, L. V. Baleeva, Z. V. Galeeva
Aim . To evaluate the role of growth differentiation factor-15 (GDF-15) in long-term prognosis in patients with uncomplicated myocardial infarction (MI). Material and methods . The study included 118 patients with uncomplicated ST-elevation and non-ST-elevation MI. In addition to the routine examination, all patients were analyzed for GDF-15, as well as the N-terminal pro-brain natriuretic peptide (NT-proBNP) by enzyme immunoassay in the first 48 hours from the onset of MI symptoms. The changes in the patients' condition were assessed by questioning after 1, 3, 6, 12 months, as well as the analysis of medical records in the event of repeated cardiovascular events and deaths. The endpoints were cardiovascular death, hospitalization for recurrent MI, and/or unstable angina. To assess the value of quantitative variables in predicting recurrent cardiovascular events, the ROC analysis was used. The survival function of patients was assessed using the Kaplan-Meier method. Results. Twelve-month follow-up revealed 29 recurrent cardiovascular events, including 2 deaths and 8 recurrent MIs. GDF-15 was predictive of recurrent cardiovascular events with a sensitivity of 77,3% and a specificity of 56,2% (ROCAUC, 0,7±0,065 (95% confidence interval (CI), 0,572-0,827), p=0,004). Patients with GDF-15 ≥2,075 ng/mL had a higher risk of recurrent cardiovascular events (hazard ratio (HR), 3,4 (95% CI, 1,342-8,613), p=0,005). Another prognostic factor influencing the rate of recurrent cardiovascular events was NT-proBNP. An NTproBNP level ≥578 pg/mL was associated with an increased risk of cardiovascular death and rehospitalization for unstable angina and recurrent MI (HR, 4,3 (95% CI 1,828-10,239), p=0,00019). Conclusion . The combined increase in GDF-15 ≥2,075 ng/mL and NT-proBNP ≥578 pg/mL in patients with uncomplicated MI increases the risk of recurrent cardiovascular events over the next 12 months (HR, 4,5 (95% CI, 2,087-9,736), p=0,00018).
的目标。目的探讨生长分化因子-15 (GDF-15)在无并发症心肌梗死(MI)患者长期预后中的作用。材料和方法。该研究包括118例无并发症st段抬高和非st段抬高的心肌梗死患者。除常规检查外,所有患者在心肌梗死症状出现后的48小时内,通过酶免疫分析法分析GDF-15以及n端脑利钠肽前体(NT-proBNP)。通过1、3、6、12个月后的询问,以及反复发生心血管事件和死亡时的医疗记录分析,评估患者病情的变化。终点为心血管死亡、复发性心肌梗死住院和/或不稳定型心绞痛。为了评估定量变量在预测心血管事件复发中的价值,采用ROC分析。采用Kaplan-Meier法评估患者的生存功能。结果。12个月随访发现29例复发性心血管事件,包括2例死亡和8例复发性MIs。GDF-15预测心血管事件复发的敏感性为77.3%,特异性为56.2% (ROCAUC, 0,7±0,065(95%可信区间(CI), 0,572-0,827), p= 0.004)。GDF-15≥2075 ng/mL的患者心血管事件复发的风险更高(危险比(HR), 3,4 (95% CI, 1,342-8,613), p= 0.005)。另一个影响心血管事件复发率的预后因素是NT-proBNP。NTproBNP水平≥578 pg/mL与心血管死亡、不稳定型心绞痛再住院和复发性心肌梗死的风险增加相关(HR, 4,3 (95% CI 1,828-10,239), p=0,00019)。结论。无并发症心肌梗死患者GDF-15≥2075 ng/mL和NT-proBNP≥578 pg/mL的联合升高增加了未来12个月心血管事件复发的风险(HR, 4,5 (95% CI, 2,087-9,736), p=0,00018)。
{"title":"Growth differentiation factor-15 — a new indicator of unfavorable prognosis in uncomplicated myocardial infarction","authors":"A. S. Sabirzyanova, A. S. Galyavich, L. V. Baleeva, Z. V. Galeeva","doi":"10.15829/1560-4071-2023-5381","DOIUrl":"https://doi.org/10.15829/1560-4071-2023-5381","url":null,"abstract":"Aim . To evaluate the role of growth differentiation factor-15 (GDF-15) in long-term prognosis in patients with uncomplicated myocardial infarction (MI). Material and methods . The study included 118 patients with uncomplicated ST-elevation and non-ST-elevation MI. In addition to the routine examination, all patients were analyzed for GDF-15, as well as the N-terminal pro-brain natriuretic peptide (NT-proBNP) by enzyme immunoassay in the first 48 hours from the onset of MI symptoms. The changes in the patients' condition were assessed by questioning after 1, 3, 6, 12 months, as well as the analysis of medical records in the event of repeated cardiovascular events and deaths. The endpoints were cardiovascular death, hospitalization for recurrent MI, and/or unstable angina. To assess the value of quantitative variables in predicting recurrent cardiovascular events, the ROC analysis was used. The survival function of patients was assessed using the Kaplan-Meier method. Results. Twelve-month follow-up revealed 29 recurrent cardiovascular events, including 2 deaths and 8 recurrent MIs. GDF-15 was predictive of recurrent cardiovascular events with a sensitivity of 77,3% and a specificity of 56,2% (ROCAUC, 0,7±0,065 (95% confidence interval (CI), 0,572-0,827), p=0,004). Patients with GDF-15 ≥2,075 ng/mL had a higher risk of recurrent cardiovascular events (hazard ratio (HR), 3,4 (95% CI, 1,342-8,613), p=0,005). Another prognostic factor influencing the rate of recurrent cardiovascular events was NT-proBNP. An NTproBNP level ≥578 pg/mL was associated with an increased risk of cardiovascular death and rehospitalization for unstable angina and recurrent MI (HR, 4,3 (95% CI 1,828-10,239), p=0,00019). Conclusion . The combined increase in GDF-15 ≥2,075 ng/mL and NT-proBNP ≥578 pg/mL in patients with uncomplicated MI increases the risk of recurrent cardiovascular events over the next 12 months (HR, 4,5 (95% CI, 2,087-9,736), p=0,00018).","PeriodicalId":21389,"journal":{"name":"Russian Journal of Cardiology","volume":"26 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136238527","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Factors and sex differences associated with intermediate probability of heart failure with preserved ejection fraction in asymptomatic patients working in the Arctic 在北极工作的无症状患者保留射血分数的心力衰竭中间概率的相关因素和性别差异
Q3 Medicine Pub Date : 2023-09-21 DOI: 10.15829/1560-40712023-5400
N. P. Shurkevich, A. S. Vetoshkin, A. A. Simonyan, L. I. Gapon, M. A. Kareva
Aim. To determine additional factors and sex differences associated with the intermediate probability of heart failure (HF) with preserved ejection fraction (HFpEF) in asymptomatic patients working in the Arctic on a rotating basis. Material and methods . In the polar village of Yamburg (68° 21' 40 "N), 99 men and 81 women with grade 1 and 2 hypertension (HTN) and normal blood pressure, comparable by age (p=0,450), length of service in the north (p=0,956), office systolic blood pressure (BP) (p=0,251), diastolic BP (p=0,579) were simultaneously examined. We performed echocardiography and assessed the risk of HFpEF by H2FPEF score (Heavy; Hypertensive; Atrial Fibrillation; Pulmonary Hypertension; Elder; Filling Pressure). A treadmill test, Baevsky index, 24-hour BP monitoring, and biochemical blood tests were performed. Results. Depending on H2FPEF score, participants were divided into groups: from 0 to 1 (group 1 — normal), from 2 to 5 (group 2 — intermediate probability of HFpEF). In men with intermediate probability of HFpEF, the Baevsky index (p=0,0048) and the incidence of resting body reserve dysaptation (p=0,0394) were higher, as well as a rapid BP increase during dosed exercise (p=0,0058) and a decrease in chronotropic reserve (p<0,0001) were noted. The presence of HTN in men increased the intermediate probability of HFpEF by 3,6 times, dyspnea at dosed exercise by 10 times, dysaptation to exercise by 5 times, the presence of left ventricular concentric remodeling by 8-10 times. In females with intermediate probability of HFpEF, dysaptation to exercise at rest (p=0,0120) and lower level of oxygen consumption during dosed exercise was more often determined (p=0,0485). The intermediate probability of HFpEF in women increased with autonomic nervous system dysfunction, an increase in the mean 24-hour systolic BP variability, the presence of dyspnea during dosed exercise (10 times), concentric left ventricular remodeling, and an increase in nonspecific inflammation markers (high-sensitivity C-reactive protein, IL-1β, IL-6). Conclusion . Early identification of additional risk factors for intermediate probability of HFpEF in asymptomatic hypertensive patients has the potential to reduce the risk of subsequent clinical heart failure, allowing focus on prevention and intervention strategies in this group of patients.
的目标。确定在北极轮流工作的无症状患者保留射血分数(HFpEF)心力衰竭(HF)的中间概率相关的其他因素和性别差异。材料和方法。在极地村庄Yamburg(北纬68°21′40”),99名男性和81名女性患有1级和2级高血压(HTN),血压正常,按年龄(p=0,450),在北方服役时间(p=0,956),办公室收缩压(p=0,251),舒张压(p=0,579)同时进行检查。我们进行了超声心动图检查,并通过H2FPEF评分评估HFpEF的风险(Heavy;高血压;心房颤动;肺动脉高压;年长的;填充压力)。进行跑步机试验、Baevsky指数、24小时血压监测和血液生化试验。结果。根据H2FPEF得分,参与者被分为组:从0到1(1组-正常),从2到5(2组- HFpEF的中等概率)。在HFpEF中等概率的男性中,Baevsky指数(p= 0.0048)和静息体储备失调发生率(p= 0.0394)较高,并且在大剂量运动期间血压快速升高(p= 0.0058)和变时性储备降低(p= 0.00001)。男性HTN的存在使HFpEF的中间概率增加3,6倍,大剂量运动时呼吸困难增加10倍,运动适应障碍增加5倍,左室同心重构增加8-10倍。在HFpEF发生率中等的女性中,休息时运动不适应(p=0,0120)和大剂量运动时较低的耗氧量水平更为常见(p=0,0485)。女性HFpEF的中间概率随着自主神经系统功能障碍、平均24小时收缩压变异性增加、大剂量运动期间出现呼吸困难(10次)、同心左心室重构和非特异性炎症标志物(高敏c反应蛋白、IL-1β、IL-6)的增加而增加。结论。早期识别无症状高血压患者发生HFpEF中间概率的其他危险因素有可能降低随后临床心力衰竭的风险,从而使这组患者能够关注预防和干预策略。
{"title":"Factors and sex differences associated with intermediate probability of heart failure with preserved ejection fraction in asymptomatic patients working in the Arctic","authors":"N. P. Shurkevich, A. S. Vetoshkin, A. A. Simonyan, L. I. Gapon, M. A. Kareva","doi":"10.15829/1560-40712023-5400","DOIUrl":"https://doi.org/10.15829/1560-40712023-5400","url":null,"abstract":"Aim. To determine additional factors and sex differences associated with the intermediate probability of heart failure (HF) with preserved ejection fraction (HFpEF) in asymptomatic patients working in the Arctic on a rotating basis. Material and methods . In the polar village of Yamburg (68° 21' 40 \"N), 99 men and 81 women with grade 1 and 2 hypertension (HTN) and normal blood pressure, comparable by age (p=0,450), length of service in the north (p=0,956), office systolic blood pressure (BP) (p=0,251), diastolic BP (p=0,579) were simultaneously examined. We performed echocardiography and assessed the risk of HFpEF by H2FPEF score (Heavy; Hypertensive; Atrial Fibrillation; Pulmonary Hypertension; Elder; Filling Pressure). A treadmill test, Baevsky index, 24-hour BP monitoring, and biochemical blood tests were performed. Results. Depending on H2FPEF score, participants were divided into groups: from 0 to 1 (group 1 — normal), from 2 to 5 (group 2 — intermediate probability of HFpEF). In men with intermediate probability of HFpEF, the Baevsky index (p=0,0048) and the incidence of resting body reserve dysaptation (p=0,0394) were higher, as well as a rapid BP increase during dosed exercise (p=0,0058) and a decrease in chronotropic reserve (p<0,0001) were noted. The presence of HTN in men increased the intermediate probability of HFpEF by 3,6 times, dyspnea at dosed exercise by 10 times, dysaptation to exercise by 5 times, the presence of left ventricular concentric remodeling by 8-10 times. In females with intermediate probability of HFpEF, dysaptation to exercise at rest (p=0,0120) and lower level of oxygen consumption during dosed exercise was more often determined (p=0,0485). The intermediate probability of HFpEF in women increased with autonomic nervous system dysfunction, an increase in the mean 24-hour systolic BP variability, the presence of dyspnea during dosed exercise (10 times), concentric left ventricular remodeling, and an increase in nonspecific inflammation markers (high-sensitivity C-reactive protein, IL-1β, IL-6). Conclusion . Early identification of additional risk factors for intermediate probability of HFpEF in asymptomatic hypertensive patients has the potential to reduce the risk of subsequent clinical heart failure, allowing focus on prevention and intervention strategies in this group of patients.","PeriodicalId":21389,"journal":{"name":"Russian Journal of Cardiology","volume":"23 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136238704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Identification of leptin resistance in patients with coronary artery disease and heart defects 冠状动脉疾病和心脏缺陷患者瘦素抵抗的鉴定
Q3 Medicine Pub Date : 2023-09-21 DOI: 10.15829/1560-4071-20235455
E. Е. Gorbatovskaya, Yu. A. Dyleva, E. V. Belik, E. G. Uchasova, R. S. Tarasov, O. V. Gruzdeva
Aim. To compare the incidence of leptin resistance (LR) in patients with acute and chronic coronary artery disease (CAD) and patients with acquired heart defects (AHD). Material and methods . The study included 234 patients: 114 patients with acute myocardial infarction (MI) and 120 patients with chronic CAD. The comparison group consisted of 48 patients with degenerative non-rheumatic AHD — aortic stenosis (AS). The control group consisted of 40 healthy volunteers. On the 1st day of hospitalization, the concentration of leptin and leptin receptor was measured, and the free leptin index (FLI) was assessed. LR was recorded at leptin >6,45 ng/ ml and FLI >25. Statistical data processing was carried out using the software package Statistica 10.0 and SPSS 17.0 for Windows. Results . Initially, LR in MI, chronic CAD and non-coronary disease was revealed in 64%, 56,2% and 25%, respectively. Significant differences in the incidence of LR were observed between patients with MI and chronic CAD relative to patients with AHD (p=0,02 and p=0,03, respectively), while no differences were found between patients with coronary pathology (p=0,82). Equation of patients for body mass index (BMI) did not affect the incidence of LR. High incidence of LR remained for patients with acute and chronic CAD, and amounted to 63% and 57,3%, respectively, while for patients with AS — 25%. Conclusion . Patients with acute and chronic CAD are characterized by a high LR incidence, in contrast to patients with AHD. The number of LR cases in patients with coronary pathology did not depend on BMI values, which indicates possible alternative leptin sources contributing the development of hyperleptinemia. In addition, studying the mechanisms underlying the leptin receptor decrease in CAD is necessary for adequate leptin effects and the prevention of LR.
的目标。比较急慢性冠状动脉疾病(CAD)和获得性心脏缺陷(AHD)患者瘦素抵抗(LR)的发生率。材料和方法。该研究包括234例患者:114例急性心肌梗死(MI)患者和120例慢性CAD患者。对照组为48例退行性非风湿性AHD主动脉瓣狭窄(AS)患者。对照组由40名健康志愿者组成。入院第1天测定两组患者瘦素及瘦素受体浓度,评估游离瘦素指数(FLI)。瘦素6、45 ng/ ml和FLI 25时记录LR。统计数据处理采用Statistica 10.0软件包和SPSS 17.0 for Windows软件。结果。最初,心肌梗死、慢性冠心病和非冠状动脉疾病的LR发生率分别为64%、56%、2%和25%。心肌梗死和慢性CAD患者的LR发生率与AHD患者相比差异有统计学意义(p= 0.02和p= 0.03),而冠状动脉病理患者的LR发生率无统计学意义(p= 0.82)。患者体重指数(BMI)方程对LR的发生率无影响。急性和慢性CAD患者的LR发生率仍然很高,分别为63%和57.3%,而AS患者的LR发生率为25%。结论。与AHD患者相比,急性和慢性CAD患者的特点是LR发生率高。冠状动脉病理患者中LR病例的数量不依赖于BMI值,这表明可能有其他瘦素来源导致高瘦素血症的发生。此外,研究CAD中瘦素受体减少的机制对于充分发挥瘦素的作用和预防LR是必要的。
{"title":"Identification of leptin resistance in patients with coronary artery disease and heart defects","authors":"E. Е. Gorbatovskaya, Yu. A. Dyleva, E. V. Belik, E. G. Uchasova, R. S. Tarasov, O. V. Gruzdeva","doi":"10.15829/1560-4071-20235455","DOIUrl":"https://doi.org/10.15829/1560-4071-20235455","url":null,"abstract":"Aim. To compare the incidence of leptin resistance (LR) in patients with acute and chronic coronary artery disease (CAD) and patients with acquired heart defects (AHD). Material and methods . The study included 234 patients: 114 patients with acute myocardial infarction (MI) and 120 patients with chronic CAD. The comparison group consisted of 48 patients with degenerative non-rheumatic AHD — aortic stenosis (AS). The control group consisted of 40 healthy volunteers. On the 1st day of hospitalization, the concentration of leptin and leptin receptor was measured, and the free leptin index (FLI) was assessed. LR was recorded at leptin &gt;6,45 ng/ ml and FLI &gt;25. Statistical data processing was carried out using the software package Statistica 10.0 and SPSS 17.0 for Windows. Results . Initially, LR in MI, chronic CAD and non-coronary disease was revealed in 64%, 56,2% and 25%, respectively. Significant differences in the incidence of LR were observed between patients with MI and chronic CAD relative to patients with AHD (p=0,02 and p=0,03, respectively), while no differences were found between patients with coronary pathology (p=0,82). Equation of patients for body mass index (BMI) did not affect the incidence of LR. High incidence of LR remained for patients with acute and chronic CAD, and amounted to 63% and 57,3%, respectively, while for patients with AS — 25%. Conclusion . Patients with acute and chronic CAD are characterized by a high LR incidence, in contrast to patients with AHD. The number of LR cases in patients with coronary pathology did not depend on BMI values, which indicates possible alternative leptin sources contributing the development of hyperleptinemia. In addition, studying the mechanisms underlying the leptin receptor decrease in CAD is necessary for adequate leptin effects and the prevention of LR.","PeriodicalId":21389,"journal":{"name":"Russian Journal of Cardiology","volume":"240 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136238714","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prevalence and clinical significance of iron deficiency in patients with acute decompensated heart failure 急性失代偿性心力衰竭患者缺铁的发生率及临床意义
Q3 Medicine Pub Date : 2023-09-21 DOI: 10.15829/1560-4071-2023-5413
E. A. Smirnova, E. V. Sedykh, S. S. Yakushin, S. V. Subbotin
Aim. To study the prevalence of iron deficiency (ID) and anemia, as well as their impact on the clinical performance and quality of life in patients with acute decompensated heart failure (ADHF). Material and methods . The work was performed as part of cross-sectional multicenter screening study of ID in patients with heart failure (HF), managed by the Russian Society of Heart Failure. We examined 80 patients hospitalized in the cardiology department due to ADHF, who signed an informed consent. The diagnosis of ADHF was based on clinical signs of decompensated heart failure requiring intravenous therapy with diuretics, vasodilators, or inotropic agents. Results. The prevalence of ID was 80,0%, anemia — 35,0%, combination of anemia and ID — 31,2%. The mean age of patients with ID was 69,4±10,9 years. Patients with ID had higher HF class (40,6% vs 6,3% without ID, p<0,001), a higher incidence of hydrothorax (65,6% vs 31,3%, p=0,012), higher N-terminal pro-brain natriuretic peptide (5155,5 [3267,3;9786,3] pg/mL vs 2055,5 [708,8;2839,0] pg/mL, p<0,001), lower 6-minute walk test distance (155,9±84,0 m vs 239,6±82,7 m in patients without ID, p=0,01), lower quality of life according to the visual analogue scale (36,4±16,3 vs 46,3±20,7, p=0,036). ID was more often recorded in patients with frailty (95,7% vs 73,7% in patients without frailty, p=0,003), requiring a higher starting dose of intravenous diuretics (50,9±18,9 mg vs 38,6±12,3 mg without ID, p=0,021). Conclusion. In patients hospitalized due to ADHF, the prevalence of ID is 80,0%, anemia — 35,0%, combination of ID and anemia — 31,2%. Patients with ID have a higher N-terminal pro-brain natriuretic peptide level, more severe signs of decompensation, which requires higher starting dose of loop diuretics. Patients with ID are more likely to have frailty, lower exercise tolerance and quality of life.
的目标。探讨急性失代偿性心力衰竭(ADHF)患者缺铁(ID)和贫血的患病率及其对临床表现和生活质量的影响。材料和方法。这项工作是作为心衰(HF)患者ID横断面多中心筛查研究的一部分进行的,由俄罗斯心力衰竭学会管理。我们对80例因ADHF住院的心内科患者进行了调查,这些患者均签署了知情同意书。ADHF的诊断是基于失代偿性心力衰竭的临床症状,需要利尿剂、血管扩张剂或肌力药物的静脉治疗。结果。ID患病率为80.0%,贫血- 35.0%,贫血合并ID - 31.2%。ID患者的平均年龄为69,4±10.9岁。ID患者有较高的HF分级(40.6% vs 6.3%,无ID者,p= 0.036),较高的胸水发生率(65,6% vs 31.3%, p= 0.012),较高的n端脑钠肽前体(5155,5 [3267,3;9786,3]pg/mL vs 2055,5 [708,8;2839,0] pg/mL, p= 0.012),较短的6分钟步行测试距离(155,9±84,0 m vs 239,6±82,7 m, p= 0.01),较低的生活质量根据视觉模拟量表(36,4±16,3 vs 46,3±20,7,p= 0.036)。ID在虚弱患者中更常见(95.7% vs 73.7%,无虚弱患者,p= 0.003),需要更高的静脉利尿剂起始剂量(50.9±18.9 mg vs 38.6±12.3 mg,无ID, p= 0.021)。结论。在ADHF住院患者中,ID患病率为80.0%,贫血患病率为35.0%,ID合并贫血患病率为31.2%。ID患者n端前脑利钠肽水平较高,代偿症状更严重,需要较高的起始剂量的环状利尿剂。ID患者更容易体弱多病,运动耐受性较低,生活质量较差。
{"title":"Prevalence and clinical significance of iron deficiency in patients with acute decompensated heart failure","authors":"E. A. Smirnova, E. V. Sedykh, S. S. Yakushin, S. V. Subbotin","doi":"10.15829/1560-4071-2023-5413","DOIUrl":"https://doi.org/10.15829/1560-4071-2023-5413","url":null,"abstract":"Aim. To study the prevalence of iron deficiency (ID) and anemia, as well as their impact on the clinical performance and quality of life in patients with acute decompensated heart failure (ADHF). Material and methods . The work was performed as part of cross-sectional multicenter screening study of ID in patients with heart failure (HF), managed by the Russian Society of Heart Failure. We examined 80 patients hospitalized in the cardiology department due to ADHF, who signed an informed consent. The diagnosis of ADHF was based on clinical signs of decompensated heart failure requiring intravenous therapy with diuretics, vasodilators, or inotropic agents. Results. The prevalence of ID was 80,0%, anemia — 35,0%, combination of anemia and ID — 31,2%. The mean age of patients with ID was 69,4±10,9 years. Patients with ID had higher HF class (40,6% vs 6,3% without ID, p<0,001), a higher incidence of hydrothorax (65,6% vs 31,3%, p=0,012), higher N-terminal pro-brain natriuretic peptide (5155,5 [3267,3;9786,3] pg/mL vs 2055,5 [708,8;2839,0] pg/mL, p<0,001), lower 6-minute walk test distance (155,9±84,0 m vs 239,6±82,7 m in patients without ID, p=0,01), lower quality of life according to the visual analogue scale (36,4±16,3 vs 46,3±20,7, p=0,036). ID was more often recorded in patients with frailty (95,7% vs 73,7% in patients without frailty, p=0,003), requiring a higher starting dose of intravenous diuretics (50,9±18,9 mg vs 38,6±12,3 mg without ID, p=0,021). Conclusion. In patients hospitalized due to ADHF, the prevalence of ID is 80,0%, anemia — 35,0%, combination of ID and anemia — 31,2%. Patients with ID have a higher N-terminal pro-brain natriuretic peptide level, more severe signs of decompensation, which requires higher starting dose of loop diuretics. Patients with ID are more likely to have frailty, lower exercise tolerance and quality of life.","PeriodicalId":21389,"journal":{"name":"Russian Journal of Cardiology","volume":"23 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136238878","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prognostic role of atrial fibrillation in patients with non-compaction cardiomyopathy 房颤对非压实性心肌病患者预后的影响
Q3 Medicine Pub Date : 2023-09-21 DOI: 10.15829/1560-4071-2023-5406
S. M. Komissarova, N. M. Rineyskaya, O. P. Melnikova, T. V. Sevruk, A. A. Efimova
Aim. To evaluate the prognostic role of atrial fibrillation (AF) as a predictor of adverse events and outcomes in a cohort of patients with non-compaction cardiomyopathy (NCCM). Material and methods . We examined 216 patients with NCCM (140 men and 76 women, median age, 39 (30; 50) years). In addition to traditional clinical methods, all patients underwent late gadolinium-enhanced cardiac magnetic resonance imaging (MRI). The endpoints of the study included progression of NYHA class III heart failure (HF) with the need for hospitalization, ventricular tachyarrhythmias, and thromboembolic events (TEEs). Results. There were 54 out of 216 (23,6%) patients with AF, of which 18 had paroxysmal AF, 16 — persistent AF, and 20 — permanent AF. During the follow-up period (median follow-up, 36 (6; 72) months), 98 out of 216 (45,4%) patients with NCCM had adverse events and outcomes as follows: 16 (7,4%) had ventricular tachyarrhythmias, of which 12 (5,6%) — sudden cardiac death with successful resuscitation and implantation of an implantable cardioverter-defibrillator; 62 (28,7%) patients had NYHA III-IV class HF progression; 20 (9,3%) patients had TEEs. The rate of adverse cardiac events was significantly higher in patients with AF (74,1% vs 35,8%, χ 2 =23,93, p<0,001) compared with patients without AF, including the incidence of TEEs (20,4% vs 5,6%, χ 2 =10,58, p=0,002) and HF progression to class III (46,3% vs 22,8%, χ 2 =10,9, p=0,002). Multivariate analysis showed that the following most significant predictors of HF progression risk: left ventricular ejection fraction (LVEF) <50% according to cardiac MRI (hazard ratio (HR), 95,8; 95% confidence interval (CI), 10,2 -898,6; p=0,0001), presence of AF (HR, 8,2; 95% CI, 2,2-31,3; p=0,0022) and left atrial volume index (LAVI) >43 ml/m 2 (HR, 5,2; 95% CI, 2,1-12,8; p=0,0004); predictors of TEE risk were the presence of AF (HR, 6,5; 95% CI, 2,0-20,8; p=0,0020) and LAVI >43 ml/m 2 (HR, 6,0; 95% CI, 1,8-19,7; p=0,036). No association of AF with ventricular tachyarrhythmias was found in the study cohort of patients with NCCM. Predictors of ventricular tachyarrhythmias were LVEF <50% (HR, 4,5; 95% CI, 2,950,4; p=0,0241) and the presence of non-sustained ventricular tachycardia (HR, 3,5; 95% CI, 1,3-9,3 p=0,0139). Conclusion. The present study shows that, along with the traditional predictor of adverse events in patients with NCCM (LVEF <50%), the identified additional predictors (AF and LAVI >43 ml/m 2 ) can be used to identify patients at high risk of complicated NCCM for the timely prevention and treatment.
的目标。评估心房颤动(AF)在非压实性心肌病(NCCM)患者队列中作为不良事件和预后预测因子的预后作用。材料和方法。我们检查了216例NCCM患者(男性140例,女性76例),中位年龄39岁(30岁;50年)。除传统临床方法外,所有患者均行晚期钆增强心脏磁共振成像(MRI)。该研究的终点包括NYHA III级心力衰竭(HF)的进展,需要住院治疗,室性心动过速和血栓栓塞事件(tee)。结果。216例房颤患者中有54例(23.6%),其中18例为阵发性房颤,16例为持续性房颤,20例为永久性房颤。72个月),216例NCCM患者中有98例(45.4%)发生不良事件和结果如下:16例(7.4%)发生室性心动过速,其中12例(5.6%)-心脏性猝死,成功复苏并植入可植入式心律转复除颤器;62例(28.7%)患者有NYHA III-IV级HF进展;20例(9.3%)患者有tee。与非房颤患者相比,房颤患者的不良心脏事件发生率显著高于非房颤患者(74,1% vs 35,8%, χ 2 =23,93, p= 0,001),包括tee的发生率(20.4% vs 5.6%, χ 2 =10,58, p=0,002)和HF进展至III级(46.3% vs 22,8%, χ 2 =10,9, p=0,002)。多因素分析显示:左心室射血分数(LVEF) <心脏MRI显示为50%(危险比(HR), 95,8;95%置信区间(CI)为10,2 -898,6;p=0,0001), AF的存在(HR, 8,2;95% ci, 2,2-31,3;p= 0.0022),左房容积指数(LAVI) >43 ml/ m2 (HR, 5,2;95% ci, 2,1-12,8;p = 0, 0004);TEE风险的预测因子为房颤(HR, 6,5;95% ci, 2,0-20,8;p=0,0020)和LAVI >43 ml/ m2 (HR, 6,0;95% ci, 1,8-19,7;p = 0036)。在NCCM患者的研究队列中,未发现房颤与室性心动过速相关。室性心动过速的预测因子为LVEF <50% (HR, 4,5;95% ci, 2,950,4;p=0,0241)和非持续性室性心动过速的存在(HR, 3,5;95% CI, 1,3-9,3 p= 0,139)。结论。本研究表明,除了NCCM患者不良事件的传统预测因子(LVEF <50%)外,确定的附加预测因子(AF和LAVI >43 ml/ m2)可用于识别复杂NCCM的高危患者,以便及时预防和治疗。
{"title":"Prognostic role of atrial fibrillation in patients with non-compaction cardiomyopathy","authors":"S. M. Komissarova, N. M. Rineyskaya, O. P. Melnikova, T. V. Sevruk, A. A. Efimova","doi":"10.15829/1560-4071-2023-5406","DOIUrl":"https://doi.org/10.15829/1560-4071-2023-5406","url":null,"abstract":"Aim. To evaluate the prognostic role of atrial fibrillation (AF) as a predictor of adverse events and outcomes in a cohort of patients with non-compaction cardiomyopathy (NCCM). Material and methods . We examined 216 patients with NCCM (140 men and 76 women, median age, 39 (30; 50) years). In addition to traditional clinical methods, all patients underwent late gadolinium-enhanced cardiac magnetic resonance imaging (MRI). The endpoints of the study included progression of NYHA class III heart failure (HF) with the need for hospitalization, ventricular tachyarrhythmias, and thromboembolic events (TEEs). Results. There were 54 out of 216 (23,6%) patients with AF, of which 18 had paroxysmal AF, 16 — persistent AF, and 20 — permanent AF. During the follow-up period (median follow-up, 36 (6; 72) months), 98 out of 216 (45,4%) patients with NCCM had adverse events and outcomes as follows: 16 (7,4%) had ventricular tachyarrhythmias, of which 12 (5,6%) — sudden cardiac death with successful resuscitation and implantation of an implantable cardioverter-defibrillator; 62 (28,7%) patients had NYHA III-IV class HF progression; 20 (9,3%) patients had TEEs. The rate of adverse cardiac events was significantly higher in patients with AF (74,1% vs 35,8%, χ 2 =23,93, p<0,001) compared with patients without AF, including the incidence of TEEs (20,4% vs 5,6%, χ 2 =10,58, p=0,002) and HF progression to class III (46,3% vs 22,8%, χ 2 =10,9, p=0,002). Multivariate analysis showed that the following most significant predictors of HF progression risk: left ventricular ejection fraction (LVEF) <50% according to cardiac MRI (hazard ratio (HR), 95,8; 95% confidence interval (CI), 10,2 -898,6; p=0,0001), presence of AF (HR, 8,2; 95% CI, 2,2-31,3; p=0,0022) and left atrial volume index (LAVI) >43 ml/m 2 (HR, 5,2; 95% CI, 2,1-12,8; p=0,0004); predictors of TEE risk were the presence of AF (HR, 6,5; 95% CI, 2,0-20,8; p=0,0020) and LAVI >43 ml/m 2 (HR, 6,0; 95% CI, 1,8-19,7; p=0,036). No association of AF with ventricular tachyarrhythmias was found in the study cohort of patients with NCCM. Predictors of ventricular tachyarrhythmias were LVEF <50% (HR, 4,5; 95% CI, 2,950,4; p=0,0241) and the presence of non-sustained ventricular tachycardia (HR, 3,5; 95% CI, 1,3-9,3 p=0,0139). Conclusion. The present study shows that, along with the traditional predictor of adverse events in patients with NCCM (LVEF <50%), the identified additional predictors (AF and LAVI >43 ml/m 2 ) can be used to identify patients at high risk of complicated NCCM for the timely prevention and treatment.","PeriodicalId":21389,"journal":{"name":"Russian Journal of Cardiology","volume":"73 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136238703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Relationship between apoptosis markers and the severity of coronary atherosclerosis and clinical and paraclinical characteristics of patients with coronary artery disease 冠状动脉疾病患者的细胞凋亡标记物与冠状动脉粥样硬化严重程度及临床和准临床特征之间的关系
Q3 Medicine Pub Date : 2023-09-18 DOI: 10.15829/1560-4071-2023-5518
E. A. Zakharyan, I. Fomochkina
Aim. To assess markers of serum apoptosis markers depending on the severity of coronary atherosclerosis, as well as to study their relationship with clinical and paraclinical characteristics of patients with coronary artery disease (CAD).Material and methods. The study included 176 people (105 men and 71 women), of which 150 were patients with an established diagnosis of CAD, 26 — healthy volunteers (control group). The patients were divided into the following groups: group 1 — with coronary atherosclerosis without stenosis (n=17); group 2 — with hemodynamically insignificant (stenosis <50%) coronary atherosclerosis (n=21); group 3 — with hemodynamically significant (stenosis >50%) coronary atherosclerosis (n=112). Group 4 was represented by healthy volunteers (n=26). Patients underwent coronary angiography using the SYNTAX score, echocardiography, extracranial artery duplex ultrasound. All subjects were studied for the serum level of apoptosis markers Bcl-2, Bax, Bcl-2/Bax, TRAIL and p53. Statistical processing was carried out using the Statistica 10.0 software. Differences were considered significant at p<0,05.Results. There was a very high correlation between the Bcl-2 (r=-0,84; p<0,001), Bax (r=0,83; p<0,001), Bcl-2/Bax (r=-0,86; p<0,001), p53 (r=0,80; p<0,001), TRAIL (r=-0,78; p<0,001) and the severity of coronary atherosclerosis. A correlation of varying strength and significance was revealed between the values of these apoptosis markers and a number of clinical and paraclinical characteristics of patients. In addition, there were significant differences (p<0,001) in Bcl-2, Bax, Bcl2/Bax, p53 and TRAIL between groups of patients with multifocal atherosclerosis, restenosis after previous revascularization and a history of myocardial infarction in comparison with patients without these signs.Conclusion. The correlations we have identified between laboratory signs of apoptosis and coronary lesions, clinical and paraclinical characteristics of patients, as well as the detected reliability of differences between groups with multifocal atherosclerosis, coronary artery restenosis and myocardial infarction in history, make it possible to consider these biomarkers as indicators of atherosclerosis severity. This can also be the basis for the development of novel treatment and diagnostic strategies.
目的根据冠状动脉粥样硬化的严重程度评估血清凋亡标志物的标记,并研究它们与冠状动脉疾病(CAD)患者的临床和辅助临床特征之间的关系。研究对象包括 176 人(男性 105 人,女性 71 人),其中 150 人为已确诊的冠状动脉粥样硬化患者,26 人为健康志愿者(对照组)。患者分为以下几组:第 1 组--冠状动脉粥样硬化,无狭窄(17 人);第 2 组--冠状动脉粥样硬化在血液动力学上不明显(狭窄 50%)(112 人)。第 4 组为健康志愿者(26 人)。患者接受了使用 SYNTAX 评分的冠状动脉造影术、超声心动图检查和颅外动脉双相超声检查。对所有受试者的血清凋亡标志物 Bcl-2、Bax、Bcl-2/Bax、TRAIL 和 p53 水平进行了研究。统计处理使用 Statistica 10.0 软件进行。P<0.05为差异显著。Bcl-2(r=-0,84;p<0,001)、Bax(r=0,83;p<0,001)、Bcl-2/Bax(r=-0,86;p<0,001)、p53(r=0,80;p<0,001)、TRAIL(r=-0,78;p<0,001)与冠状动脉粥样硬化的严重程度有很高的相关性。这些细胞凋亡标志物的值与患者的一些临床和准临床特征之间存在不同强度和意义的相关性。此外,多灶性动脉粥样硬化、既往血管再通后再狭窄和有心肌梗死病史的患者组与无上述症状的患者组之间的Bcl-2、Bax、Bcl2/Bax、p53和TRAIL存在明显差异(p<0.001)。我们所发现的细胞凋亡的实验室迹象与冠状动脉病变、患者的临床和辅助临床特征之间的相关性,以及多灶性动脉粥样硬化、冠状动脉再狭窄和心肌梗死病史组之间差异的可靠性,使我们有可能将这些生物标志物视为动脉粥样硬化严重程度的指标。这也可以作为开发新型治疗和诊断策略的基础。
{"title":"Relationship between apoptosis markers and the severity of coronary atherosclerosis and clinical and paraclinical characteristics of patients with coronary artery disease","authors":"E. A. Zakharyan, I. Fomochkina","doi":"10.15829/1560-4071-2023-5518","DOIUrl":"https://doi.org/10.15829/1560-4071-2023-5518","url":null,"abstract":"Aim. To assess markers of serum apoptosis markers depending on the severity of coronary atherosclerosis, as well as to study their relationship with clinical and paraclinical characteristics of patients with coronary artery disease (CAD).Material and methods. The study included 176 people (105 men and 71 women), of which 150 were patients with an established diagnosis of CAD, 26 — healthy volunteers (control group). The patients were divided into the following groups: group 1 — with coronary atherosclerosis without stenosis (n=17); group 2 — with hemodynamically insignificant (stenosis <50%) coronary atherosclerosis (n=21); group 3 — with hemodynamically significant (stenosis >50%) coronary atherosclerosis (n=112). Group 4 was represented by healthy volunteers (n=26). Patients underwent coronary angiography using the SYNTAX score, echocardiography, extracranial artery duplex ultrasound. All subjects were studied for the serum level of apoptosis markers Bcl-2, Bax, Bcl-2/Bax, TRAIL and p53. Statistical processing was carried out using the Statistica 10.0 software. Differences were considered significant at p<0,05.Results. There was a very high correlation between the Bcl-2 (r=-0,84; p<0,001), Bax (r=0,83; p<0,001), Bcl-2/Bax (r=-0,86; p<0,001), p53 (r=0,80; p<0,001), TRAIL (r=-0,78; p<0,001) and the severity of coronary atherosclerosis. A correlation of varying strength and significance was revealed between the values of these apoptosis markers and a number of clinical and paraclinical characteristics of patients. In addition, there were significant differences (p<0,001) in Bcl-2, Bax, Bcl2/Bax, p53 and TRAIL between groups of patients with multifocal atherosclerosis, restenosis after previous revascularization and a history of myocardial infarction in comparison with patients without these signs.Conclusion. The correlations we have identified between laboratory signs of apoptosis and coronary lesions, clinical and paraclinical characteristics of patients, as well as the detected reliability of differences between groups with multifocal atherosclerosis, coronary artery restenosis and myocardial infarction in history, make it possible to consider these biomarkers as indicators of atherosclerosis severity. This can also be the basis for the development of novel treatment and diagnostic strategies.","PeriodicalId":21389,"journal":{"name":"Russian Journal of Cardiology","volume":"28 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139339050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pulse oximetry methods: opportunities and limitations 脉搏血氧测定方法:机遇与局限
Q3 Medicine Pub Date : 2023-09-12 DOI: 10.15829/15604071-2023-5467
A. A. Garanin, V. A. Dyachkov, A. O. Rubanenko, O. A. Reprintseva, D. V. Duplyakov
The aim of this review was to evaluate the current literature on various methods of pulse oximetry, their advantages and disadvantages. Modern pulse oximetry methods generally correlate well with invasive saturation monitoring, which makes it possible to be widely used in clinical practice. At the same time, in order to improve the accuracy of saturation measurements, existing limitations of various pulse oximetry methods should be taken into account. The emergence and introduction into clinical practice of reflectance pulse oximetry can largely compensate for the limitations of traditional transmission pulse oximetry regarding peripheral hypoperfusion, low response time, and features of patient's nails. In the event of special situations when pulse oximetry may not be accurate enough (carbon monoxide poisoning, methemoglobinemia, severe anemia, severe tricuspid insufficiency, etc.), a thorough clinical assessment of the patient is recommen ded, as well as invasive saturation monitoring.
本综述的目的是评价目前关于脉搏血氧测定的各种方法及其优缺点的文献。现代脉搏血氧仪与有创血饱和度监测具有良好的相关性,为其在临床中的广泛应用提供了可能。同时,为了提高饱和度测量的准确性,应考虑到各种脉搏血氧测定方法存在的局限性。反射式脉搏血氧仪的出现和引入临床实践,在很大程度上弥补了传统透射式脉搏血氧仪在外周灌注不足、反应时间短以及患者指甲特征等方面的局限性。在脉搏血氧测量可能不够准确的特殊情况下(一氧化碳中毒、高铁血红蛋白血症、严重贫血、严重三尖瓣功能不全等),建议对患者进行彻底的临床评估,并进行有创饱和度监测。
{"title":"Pulse oximetry methods: opportunities and limitations","authors":"A. A. Garanin, V. A. Dyachkov, A. O. Rubanenko, O. A. Reprintseva, D. V. Duplyakov","doi":"10.15829/15604071-2023-5467","DOIUrl":"https://doi.org/10.15829/15604071-2023-5467","url":null,"abstract":"The aim of this review was to evaluate the current literature on various methods of pulse oximetry, their advantages and disadvantages. Modern pulse oximetry methods generally correlate well with invasive saturation monitoring, which makes it possible to be widely used in clinical practice. At the same time, in order to improve the accuracy of saturation measurements, existing limitations of various pulse oximetry methods should be taken into account. The emergence and introduction into clinical practice of reflectance pulse oximetry can largely compensate for the limitations of traditional transmission pulse oximetry regarding peripheral hypoperfusion, low response time, and features of patient's nails. In the event of special situations when pulse oximetry may not be accurate enough (carbon monoxide poisoning, methemoglobinemia, severe anemia, severe tricuspid insufficiency, etc.), a thorough clinical assessment of the patient is recommen ded, as well as invasive saturation monitoring.","PeriodicalId":21389,"journal":{"name":"Russian Journal of Cardiology","volume":"63 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135885106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ultrasound potential in sarcopenic obesity diagnosis: a literature review 超声诊断肌肉减少型肥胖的潜力:文献综述
Q3 Medicine Pub Date : 2023-09-12 DOI: 10.15829/1560-4071-2023-5345
D. A. Tsygankov, K. E. Krivoshapova, D. P. Tsygankova
With an increase in the average life expectancy of the population, the prevalence of sarcopenic obesity (SO) is correspondingly growing. Existing definitions of SO are based on description of sarcopenia and obesity, but there is currently no consensus defining thresholds for either of these conditions, making an accurate diagnosis difficult. At the same time, its treatment is important to prevent disability in the elderly. In this regard, the purpose of this review was to analyze the ultrasound potential for SO diagnosis. Since ultrasound is cheaper, more portable, and more accessible than other methods, it has the potential to be widely used as a clinical screening tool for identifying people with SO. Also, this method can be used to diagnose obesity, thereby leveling the errors in body mass index.
随着人口平均预期寿命的增加,肌肉减少性肥胖(SO)的患病率也相应增加。现有的SO定义是基于对肌肉减少症和肥胖的描述,但目前对这两种疾病的阈值没有共识,这使得准确诊断变得困难。同时,其治疗对预防老年人残疾也很重要。在这方面,本综述的目的是分析超声诊断SO的潜力。由于超声比其他方法更便宜,更便携,更容易获得,因此它有可能被广泛用作识别SO患者的临床筛查工具。此外,该方法还可以用于肥胖诊断,从而弥补体重指数的误差。
{"title":"Ultrasound potential in sarcopenic obesity diagnosis: a literature review","authors":"D. A. Tsygankov, K. E. Krivoshapova, D. P. Tsygankova","doi":"10.15829/1560-4071-2023-5345","DOIUrl":"https://doi.org/10.15829/1560-4071-2023-5345","url":null,"abstract":"With an increase in the average life expectancy of the population, the prevalence of sarcopenic obesity (SO) is correspondingly growing. Existing definitions of SO are based on description of sarcopenia and obesity, but there is currently no consensus defining thresholds for either of these conditions, making an accurate diagnosis difficult. At the same time, its treatment is important to prevent disability in the elderly. In this regard, the purpose of this review was to analyze the ultrasound potential for SO diagnosis. Since ultrasound is cheaper, more portable, and more accessible than other methods, it has the potential to be widely used as a clinical screening tool for identifying people with SO. Also, this method can be used to diagnose obesity, thereby leveling the errors in body mass index.","PeriodicalId":21389,"journal":{"name":"Russian Journal of Cardiology","volume":"363 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135885579","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Features of phenotyping patients with heart failure with preserved ejection fraction 保留射血分数的心力衰竭患者的表型特征
Q3 Medicine Pub Date : 2023-09-12 DOI: 10.15829/1560-4071-2023-5348
E. K. Serezhina, A. G. Obrezan
The current classification of heart failure (HF) is based on the myocardium systolic function. However, due to the polyetiological nature of the HF with preserved ejection fraction (HFpEF) and its increasing prevalence and clinical significance, a more advanced approach to the clinical assessment of patients is needed to determine the management tactics focused on the patient's phenotype. At the same time, a single algorithm for phenotyping patients with HF has not been formulated yet. There is also no terminological unity in approaches. A review of 47 original articles published in the period from 2015 to 2022 in English on Elsevier, Pubmed, Web of Science databases with a following keywords "HFpEF", "phenotype", "clusters", "phenotypic spectrum", "diastolic dysfunction" makes it possible to identify several different approaches to phenotyping HFpEF, which are based on the etiology, pathophysiological mechanisms or clinical manifestations. Differences in the algorithms used for classification lead to the formation of groups of patients with different characteristics. Today it becomes obvious that in order to develop an optimal phenotyping approach and patient-oriented management of HFpEF, a combined analysis of a large number of anamnestic, clinical and paraclinical data is necessary. To solve such a problem, unified clustering system for HFpEF types should be created, which will be basis for phenotyping patients proposed by the authors.
目前心衰(HF)的分类是基于心肌收缩功能。然而,由于具有保留射血分数(HFpEF)的心衰的多学性质及其日益增加的患病率和临床意义,需要一种更先进的患者临床评估方法来确定以患者表型为重点的管理策略。与此同时,一种用于HF患者表型的单一算法尚未制定。在方法上也没有术语上的统一。通过对2015 - 2022年在Elsevier、Pubmed、Web of Science数据库中发表的47篇英文原创文章的回顾,检索关键词为“HFpEF”、“表型”、“聚类”、“表型谱”、“舒张功能障碍”,可以确定几种不同的HFpEF表型分析方法,这些方法基于病因、病理生理机制或临床表现。用于分类的算法的差异导致形成具有不同特征的患者群体。今天,很明显,为了开发一种最佳的表现型方法和以患者为导向的HFpEF管理,有必要对大量的记忆、临床和临床旁数据进行综合分析。为了解决这一问题,需要建立统一的HFpEF分型聚类系统,这将是作者提出的患者表型分型的基础。
{"title":"Features of phenotyping patients with heart failure with preserved ejection fraction","authors":"E. K. Serezhina, A. G. Obrezan","doi":"10.15829/1560-4071-2023-5348","DOIUrl":"https://doi.org/10.15829/1560-4071-2023-5348","url":null,"abstract":"The current classification of heart failure (HF) is based on the myocardium systolic function. However, due to the polyetiological nature of the HF with preserved ejection fraction (HFpEF) and its increasing prevalence and clinical significance, a more advanced approach to the clinical assessment of patients is needed to determine the management tactics focused on the patient's phenotype. At the same time, a single algorithm for phenotyping patients with HF has not been formulated yet. There is also no terminological unity in approaches. A review of 47 original articles published in the period from 2015 to 2022 in English on Elsevier, Pubmed, Web of Science databases with a following keywords \"HFpEF\", \"phenotype\", \"clusters\", \"phenotypic spectrum\", \"diastolic dysfunction\" makes it possible to identify several different approaches to phenotyping HFpEF, which are based on the etiology, pathophysiological mechanisms or clinical manifestations. Differences in the algorithms used for classification lead to the formation of groups of patients with different characteristics. Today it becomes obvious that in order to develop an optimal phenotyping approach and patient-oriented management of HFpEF, a combined analysis of a large number of anamnestic, clinical and paraclinical data is necessary. To solve such a problem, unified clustering system for HFpEF types should be created, which will be basis for phenotyping patients proposed by the authors.","PeriodicalId":21389,"journal":{"name":"Russian Journal of Cardiology","volume":"41 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135885878","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Principles for diagnosing heart failure with preserved ejection fraction 保留射血分数诊断心力衰竭的原则
Q3 Medicine Pub Date : 2023-09-12 DOI: 10.15829/1560-4071-2023-5448
N. E. Shirokov, E. I. Yaroslavskaya, D. V. Krinochkin, N. A. Musikhina, T. P. Gizatulina, T. N. Enina, T. I. Petelina, A. M. Soldatova, E. P. Samoilova, N. O. Pogorelov, L. I. Gapon
Low-grade systemic inflammation, myocardial stress, and extracellular matrix fibrosis lead to heart failure with preserved ejection fraction (HFpEF). The HFA-PEFF diagnostic algorithm and the H2FPEF score are recommended for detecting HFpEF. Their low compliance is the reason for improving the methods for diagnosing HFpEF. Modern paraclinical diagnostics of HFpEF includes an assessment of the left ventricular filling pressure during diastolic stress test. Phase analysis of left atrial strain during resting echocardiography may be promising to conclude an increase in mean left atrial pressure. Research interest is growing in relation to biomarkers involved in the regulation of collagen synthesis. Together, paraclinical diagnostics help to characterize sequential morphofunctional cardiac remodeling, increasing the possibility of HFpEF detection.
低度全身炎症、心肌应激和细胞外基质纤维化可导致具有保留射血分数(HFpEF)的心力衰竭。推荐使用HFA-PEFF诊断算法和H2FPEF评分检测HFpEF。它们的低依从性是改进HFpEF诊断方法的原因。HFpEF的现代临床诊断包括在舒张压力测试中评估左心室充盈压力。静息超声心动图左房应变的相位分析可能有助于得出左房平均压升高的结论。研究兴趣是越来越多的生物标志物参与胶原蛋白合成的调节。总之,临床旁诊断有助于描述顺序形态功能心脏重构,增加HFpEF检测的可能性。
{"title":"Principles for diagnosing heart failure with preserved ejection fraction","authors":"N. E. Shirokov, E. I. Yaroslavskaya, D. V. Krinochkin, N. A. Musikhina, T. P. Gizatulina, T. N. Enina, T. I. Petelina, A. M. Soldatova, E. P. Samoilova, N. O. Pogorelov, L. I. Gapon","doi":"10.15829/1560-4071-2023-5448","DOIUrl":"https://doi.org/10.15829/1560-4071-2023-5448","url":null,"abstract":"Low-grade systemic inflammation, myocardial stress, and extracellular matrix fibrosis lead to heart failure with preserved ejection fraction (HFpEF). The HFA-PEFF diagnostic algorithm and the H2FPEF score are recommended for detecting HFpEF. Their low compliance is the reason for improving the methods for diagnosing HFpEF. Modern paraclinical diagnostics of HFpEF includes an assessment of the left ventricular filling pressure during diastolic stress test. Phase analysis of left atrial strain during resting echocardiography may be promising to conclude an increase in mean left atrial pressure. Research interest is growing in relation to biomarkers involved in the regulation of collagen synthesis. Together, paraclinical diagnostics help to characterize sequential morphofunctional cardiac remodeling, increasing the possibility of HFpEF detection.","PeriodicalId":21389,"journal":{"name":"Russian Journal of Cardiology","volume":"39 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135884197","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Russian Journal of Cardiology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1